Maagh Petra, Christoph Arnd, Müller Markus Sebastian, Dopp Henning, Plehn Gunnar, Meissner Axel
Department of Cardiology, Electrophysiology and Intensive Care, Klinikum Merheim, University Witten/Herdecke/Germany, Ostmerheimer Str. 200, 51109, Cologne, Germany.
Department of Cardiology, Malteser Krankenhaus St. Anna, Albertus-Magnus-Straße 33, 47259, Duisburg, Germany.
J Interv Card Electrophysiol. 2018 Mar;51(2):169-181. doi: 10.1007/s10840-018-0311-9. Epub 2018 Jan 22.
This study was conducted with the purpose of determining whether or not the potential technical advantages of multi-electrode mapping catheters in catheter ablation (CA) of ventricular tachycardia (VT) result in any relevant clinical benefit for VT patients.
A single-center VT study, having taken place from 2012 to 2014 using a standard 3.5-mm catheter (Thermocool SF® group 1) and from 2014 to 2016 using a 1-mm multi-electrode-mapping catheter (PentaRay® group 2), was conducted. The endpoint was the complete elimination of late potentials (LPs), local abnormal ventricular activities (LAVA), and VT non-inducibility. Follow-up consisted of device interrogation to monitor for VT recurrence.
Out of 74 VT patients aged 64.5 ± 12.0 years (66 male [89.2%], 56 with ICM [75.7%], and 18 with NICM [24.3%)]), 48 patients (64.9%) were investigated in group 1 and 26 (35.1%) in group 2. Using the multi-point acquisition approach, a tendency to require less mapping time (group 1 65.2 ± 37.6 min, group 2 55.6 ± 34.4 min, p ns) was determined. During 12-month follow-up, 57 patients had freedom from VT recurrences (79.2%). The result was insignificant between the groups (38 patients (79.2%) in group 1 and 19 patients (73.1%) in group 2).
In a single-center observational study, both conventional and high-density mapping approaches in VT patients are comparable in terms of procedure duration and outcome. Mapping time when using a multi-electrode catheter seems to have the tendency of being shorter. We should be encouraged to recruit more patients comparing the benefit of different catheter types.
本研究旨在确定多电极标测导管在室性心动过速(VT)导管消融(CA)中的潜在技术优势是否能给VT患者带来任何相关的临床益处。
开展了一项单中心VT研究,2012年至2014年使用标准3.5毫米导管(Thermocool SF®组1),2014年至2016年使用1毫米多电极标测导管(PentaRay®组2)。终点是完全消除晚期电位(LPs)、局部异常心室活动(LAVA)和VT不可诱发。随访包括通过设备问询来监测VT复发情况。
在74例年龄为64.5±12.0岁的VT患者中(66例男性[89.2%],56例患有缺血性心肌病[ICM][75.7%],18例患有非缺血性心肌病[NICM][24.3%]),48例患者(64.9%)在组1接受研究,26例(35.1%)在组2接受研究。采用多点采集方法时,确定了所需标测时间有缩短的趋势(组1为65.2±37.6分钟,组2为55.6±34.4分钟,p无统计学意义)。在12个月的随访期间,57例患者无VT复发(79.2%)。两组之间结果无显著差异(组1有38例患者[79.2%],组2有19例患者[73.1%])。
在一项单中心观察性研究中,VT患者的传统标测方法和高密度标测方法在手术持续时间和结果方面具有可比性。使用多电极导管时的标测时间似乎有缩短的趋势。应鼓励招募更多患者以比较不同导管类型的益处。